Table 5.
Drug Susceptibility Profiles of patients with HIV Drug Resistance Mutations Detected
| Patient No. | Regimen | Drug Resistance Mutation Types | Susceptibility to 1 L Drugs | Susceptibility to 2 L Drugs | 2 L GSS | Subtype | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRTIs | NNRTIs | PIs | ABC | AZT | FTC | 3TC | TDF | EFV | ETR | NVP | RPV | DRV/r | ATV/r | LPV/r | ||||
| 1 | bOthers/FTC/NVP | None | V90I | K20I | S | S | aS | S | aS | S | S | aS | S | S | S | S | 3.0 | 02_AG |
| 2 | TDF/FTC/NVP | None | V90IV | K20I | S | S | aS | S | aS | S | S | aS | S | S | S | S | 3.0 | 02_AG |
| 3 | AZT/3TC/EFV | None | None | M46 L, K20I | S | aS | S | aS | S | aS | S | S | S | S | S | S | 2.75 | G |
| 4 | #Others/3TC/EFV | None | None | L10I, L23IL | S | aS | S | aS | S | *S | S | S | S | S | S | S | 3.0 | A1 |
| 5 | AZT/3TC/NVP | None | E138EG | None | S | aS | S | aS | S | S | S | *S | L | S | S | S | 3.0 | C |
| 6 | TDF/FTC/EFV | None | K103Q, E138AE | K20I | S | S | aS | S | aS | aS | S | S | L | S | S | S | 3.0 | G |
| 7 | AZT/3TC/NVP | None | V90IV, V108IV | None | S | aS | S | aS | S | S | S | aL | S | S | S | S | 3.0 | J |
| 8 | AZT/3TC/NVP | None | V108I | K20I | S | aS | S | aS | S | S | S | aL | S | S | S | S | 3.0 | G |
| 9 | AZT/3TC/EFV | None | K103 N | K20I | S | aS | S | aS | S | aH | S | H | S | S | S | S | 3.0 | G |
| 10 | AZT/3TC/EFV | None | V106A, F227 L | K20I | S | aS | S | aS | S | aH | S | H | S | S | S | S | 3.0 | 02_AG |
| 11 | bOthers/FTC/NVP | None | K103KN | K20I | S | S | aS | S | aS | H | S | aH | S | S | S | S | 3.0 | 02_AG |
| 12 | TDF/FTC/NVP | None | V90I, K103 N | K20I | S | S | aS | S | aS | H | S | aH | S | S | S | S | 3.0 | 02_AG |
| 13 | AZT/3TC/NVP | M184 V | K103 N, E138A | K20I | L | aS | H | aH | S | H | S | aH | L | S | S | S | 2.0 | G |
| 14 | AZT/3TC/EFV | D67DN, K70R, M184 V, K219E | K103 N, V108I | K20I | L | aL | H | aH | L | aH | S | H | S | S | S | S | 1.5 | 02_AG |
| 15 | TDF/3TC/EFV | K70E, M184 V | K103 N, V108I, H221Y | L10I, K20I | L | S | H | aH | aL | aH | S | H | S | S | S | S | 2.0 | 02_AG |
| 16 | AZT/3TC/NVP | M184 V | A98AG, K101E, Y181C | K20I | L | aS | H | aH | S | L | L | aH | H | S | S | S | 2.0 | 02_AG |
S Susceptible and Potential low-level resistance, L Low-level resistance and Intermediate-level resistance, H High-level resistance. NRTIs Nucleoside Reverse Transcriptase Inhibitors, NNRTIs Non-Nucleoside Reverse Transcriptase Inhibitors, PIs Protease Inhibitors; 1 L-First-line; 2 L = Second-line: GSS Genotype Sensitivity Score. aIndicate drugs in patient’s First-line regimen; bOthers = Backbone NRTI was switched